ZD1839 (???Iressa???)*,??? as an Anticancer Agent

Drugs - Tập 60 Số Supplement 1 - Trang 33-40 - 2000
Jos� Baselga1, Steven D. Averbuch2
1Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
2AstraZeneca Pharmaceuticals, Wilmington, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Olayioye, 2000, EMBO J, 19, 3159, 10.1093/emboj/19.13.3159

Lemmon, 1994, Trends Biochem Sci, 19, 459, 10.1016/0968-0004(94)90130-9

Favoni, 2000, Pharmacol Rev, 52, 179

Aaronson, 1991, Science, 254, 1146, 10.1126/science.1659742

Wells, 1999, Int J Biochem Cell Biol, 31, 637, 10.1016/S1357-2725(99)00015-1

Woodburn, 1999, Pharmacol Ther, 82, 241, 10.1016/S0163-7258(98)00045-X

Salomon, 1995, Crit Rev Oncol Hematol, 19, 183, 10.1016/1040-8428(94)00144-I

Voldborg, 1997, Ann Oncol, 8, 1197, 10.1023/A:1008209720526

Batra, 1995, Cell Growth Differ, 6, 1251

Chu, 1997, Biochem J, 324, 855, 10.1042/bj3240855

Pawson, 1992, Curr Opin Genet Dev, 2, 4, 10.1016/S0959-437X(05)80314-4

Woodburn, 1996, Proc Am Assoc Cancer Res, 36, 390

Lane, 2000, Mol Cell Biol, 20, 3210, 10.1128/MCB.20.9.3210-3223.2000

Ciardiello, 2000, Clin Cancer Res, 6, 2053

Kelly, 1998, Ann Oncol, 2, 109

Goss, 2000, Proc Am Soc Clin Oncol, 19, 225a

Baselga, 2000, Proc Am Soc Clin Oncol, 19, 177a

Nakagawa, 2000, Proc Am Soc Clin Oncol, 19, 183a

Ferry, 2000, Proc Am Soc Clin Oncol, 19, 3a